IN THE CLAIMS:

1-12. (Cancelled)

13. (Currently amended) An antigen composition comprising an *E. rhusiopathiae* culture fluid fraction and a stabilizing agent, wherein the *E. rhusiopathiae* culture is inactivated and the culture fluid fraction is substantially free of cells of *E. rhusiopathiae*, and wherein the stabilizing agent is a metal hydroxide, a metal phosphate, an aluminum hydroxide gel, a calcium phosphate gel, a zinc hydroxide/calcium hydroxide gel or an alum.

14. (Canceled)

15. (Previously presented) The antigen composition of Claim 13, wherein the *E. rhusiopathiae* culture is inactivated with formalin or with beta propiolactone.

16. (Currently amended) The antigen composition of Claim 13, wherein the fluid fraction is concentrated 6 to 20~~X~~ fold.

17. (Currently amended) A vaccine composition comprising:

(1) an antigen composition; and,

(2) an adjuvant composition,

wherein the antigen composition comprises an *E. rhusiopathiae* culture fluid fraction and a stabilizing agent, the *E. rhusiopathiae* culture is inactivated and the culture fluid fraction is substantially free of cells of *E. rhusiopathiae*; wherein the stabilizing agent is a metal hydroxide, a metal phosphate, an aluminum hydroxide gel, a calcium phosphate gel, a zinc hydroxide/calcium hydroxide gel or an alum, and wherein the adjuvant composition comprises from about 0.25% to about 12.5% v/v of a lecithin, from about 1% to about 23% v/v of an oil and from about 1.5% to about 8% v/v of an amphiphilic surfactant in said vaccine composition.

18-23. (Canceled)

24. (Previously presented) The antigen composition of Claim 13, wherein said stabilizing agent is aluminum hydroxide.

25. (Previously presented) The antigen composition of Claim 13, wherein said stabilizing agent, aluminum hydroxide, is added to the concentrated composition to a final concentration of 30% v/v.

26. (Previously presented) The vaccine composition of Claim 17, wherein said stabilizing agent is aluminum hydroxide.

27. (Previously presented) The vaccine composition of Claim 17, wherein said stabilizing agent, aluminum hydroxide, is added to the concentrated composition to a final concentration of 30% v/v.

28. (Currently amended) The vaccine composition of Claim 17, wherein said adjuvant composition comprises about 2% v/v lecithin, about 18% v/v mineral oil, and about ~~5.6% v/v Tween 80 and about 2.4% v/v Span 80~~ 8% v/v of an amphiphilic surfactant with the remaining volume being a saline solution.

29. (Canceled)

30. (Currently amended) A vaccine composition comprising:

(1) an antigen composition; and,

(2) an adjuvant composition,

wherein the antigen composition comprises an *E. rhusiopathiae* culture fluid fraction and a stabilizing agent, wherein the stabilizing agent is aluminum hydroxide gel and is present at about 30% v/v in said vaccine composition; wherein the *E. rhusiopathiae* culture is inactivated and the culture fluid fraction is substantially free of cells of *E. rhusiopathiae*; and, wherein the adjuvant composition comprises about 2% v/v lecithin, about 18% v/v mineral oil,

and about ~~5.6% v/v Tween 80 and about 2.4% v/v Span 80~~ 8% v/v of an amphiphilic surfactant with the remaining volume being a saline solution.

31. (New) The vaccine composition of Claim 30, wherein said composition is stable at 2°C to 8°C for at least one year and provides immunity to weaned pigs for six months.